Avastin Compounding Does Not Increase Endophthalmitis Risk, Study Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Observational cohort data suggest infection risk is lower with off-label use of compounded Avastin than with Genentech's approved ophthalmic treatment, Lucentis, although not statistically significant.